Figure 3.
Observed 3‐ to 6‐month treatment scaling factor is independent of various covariates tested. Scaling factor λ was not statistically significantly impacted by the various covariates tested, including (a) drug class, (b) baseline DAS28 score, (c) the magnitude of control arm ACR50 at 3 months, and (d) averaged patient disease duration. Dotted line shows the model‐predicted scaling factor (λ = 0.997). Symbol size in scatter plots reflects the sample size in each treatment arm.